Antibiotic consumption of inpatients with inflammatory bowel disease during 2015-2024 and future prediction: Evidence from a general hospital

Table 1 Description of study population, n (%)

Variables	Antibiotics exposure (n = 372)	Non-antibiotics exposure (n = 1613)	P value
Age, year, median IQR	50.00 (33.00, 62.00)	37.00 (25.00, 53.00)	< 0.001
Gender			0.020
Male	264 (20.5)	1024 (79.5)
Female	108 (15.9)	571 (84.1)
Subtypes			< 0.001
UC	192 (23.8)	615 (76.2)
CD	180 (15.3)	998 (84.7)
Length of stay, day(s), median (IQR)	11.00 (7.00, 14.00)	1.00 (1.00, 4.00)1	< 0.001
Hospitalization costs, 1000 CNY, median (IQR)	8.94 (5.81, 15.74)	3.15 (0.33, 6.14)	< 0.001

¹Totally 1092 of 1613 admissions (67.7%) within one hospital day for intravenous biologic.

IQR: Interquartile range; UC: Ulcerative colitis; CD: Crohn’s disease; CNY: Chinese Yuan.

Table 2 Clinical characteristics and antibiotic consumption differences between 2015-2019 and 2020-2024 (inflammatory bowel disease population), n (%)

Variables	2015-2019 (n = 102)	2020-2024 (n = 270)	P value
Age, year, median (IQR)	49.50 (37.00, 61.00)	50.00 (31.50, 62.00)	0.887
Length of stay, day(s), median (IQR)	10.00 (6.00, 14.00)	11.00 (7.00, 15.00)	0.379
Hospitalization costs, 1000 CNY, median (IQR)	7.63 (5.27, 15.11)	9.72 (5.94, 16.36)	0.812
Rate, %	33.89	15.93	< 0.001
DDDs per 100 bed-days, median (IQR)	49.54 (24.29, 78.57)	68.73 (43.75, 85.96)	< 0.001
Classifications
β-lactam antimicrobials/penicillins	44 (43.2)	140 (51.8)	0.134
Cephalosporins	34 (33.3)	68 (25.2)	0.116
Fluoroquinolones	11 (10.8)	39 (14.4)	0.356
Imidazole derivatives	13 (12.7)	10 (3.8)	0.001
Carbapenems	0 (0)	5 (1.9)
Glycopeptide antibacterials	0 (0)	6 (2.2)
Other antibacterials	0 (0)	2 (0.7)

IQR: Interquartile range; CNY: Chinese Yuan; DDD: Defined daily dose.